Kronos Bio, Inc. (KRON)

Kronos Bio Statistics

Total Valuation

Kronos Bio has a market cap or net worth of $50.30 million. The enterprise value is -$37.22 million.

Market Cap	50.30M
Enterprise Value	-37.22M

Important Dates

The last earnings date was Tuesday, March 18, 2025, after market close.

Earnings Date	Mar 18, 2025
Ex-Dividend Date	n/a

Share Statistics

Kronos Bio has 60.97 million shares outstanding. The number of shares has increased by 4.03% in one year.

Current Share Class	60.97M
Shares Outstanding	60.97M
Shares Change (YoY)	+4.03%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	28.49%
Owned by Institutions (%)	32.03%
Float	43.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.03
Forward PS	n/a
PB Ratio	0.57
P/TBV Ratio	0.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.28.

Current Ratio	7.54
Quick Ratio	7.36
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -69.80% and return on invested capital (ROIC) is -26.44%.

Return on Equity (ROE)	-69.80%
Return on Assets (ROA)	-23.48%
Return on Invested Capital (ROIC)	-26.44%
Return on Capital Employed (ROCE)	-58.15%
Revenue Per Employee	$984,800
Profits Per Employee	-$8.61M
Employee Count	10
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.47% in the last 52 weeks. The beta is 1.80, so Kronos Bio's price volatility has been higher than the market average.

Beta (5Y)	1.80
52-Week Price Change	-33.47%
50-Day Moving Average	0.96
200-Day Moving Average	1.01
Relative Strength Index (RSI)	27.60
Average Volume (20 Days)	165,877

Short Selling Information

The latest short interest is 747,980, so 1.23% of the outstanding shares have been sold short.

Short Interest	747,980
Short Previous Month	863,468
Short % of Shares Out	1.23%
Short % of Float	1.72%
Short Ratio (days to cover)	4.62

Income Statement

In the last 12 months, Kronos Bio had revenue of $9.85 million and -$86.08 million in losses. Loss per share was -$1.43.

Revenue	9.85M
Gross Profit	9.85M
Operating Income	-63.43M
Pretax Income	-102.85M
Net Income	-86.08M
EBITDA	-61.72M
EBIT	-63.43M
Loss Per Share	-$1.43

Balance Sheet

The company has $112.42 million in cash and $24.90 million in debt, giving a net cash position of $87.52 million or $1.44 per share.

Cash & Cash Equivalents	112.42M
Total Debt	24.90M
Net Cash	87.52M
Net Cash Per Share	$1.44
Equity (Book Value)	87.58M
Book Value Per Share	1.45
Working Capital	99.95M

Cash Flow

In the last 12 months, operating cash flow was -$65.44 million and capital expenditures -$4,000, giving a free cash flow of -$65.44 million.

Operating Cash Flow	-65.44M
Capital Expenditures	-4,000
Free Cash Flow	-65.44M
FCF Per Share	-$1.07

Margins

Gross Margin	100.00%
Operating Margin	-644.11%
Pretax Margin	-874.08%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kronos Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.03%
Shareholder Yield	n/a
Earnings Yield	-171.13%
FCF Yield	-130.10%

Analyst Forecast

The average price target for Kronos Bio is $1.63, which is 97.58% higher than the current price. The consensus rating is "Buy".

Price Target	$1.63
Price Target Difference	97.58%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	48.62%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kronos Bio has an Altman Z-Score of -6.31 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.31
Piotroski F-Score	3